Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitazoxanide for Moderate to Severe COVID-19 Pneumonia
NCT04561219Phase 2Completed
- Sponsor
- Federal University of Rio de Janeiro
- Start
- Apr 2020
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in COVID-19 pneumonia comparing Nitazoxanide with Placebo (2 arms). Primary endpoint: Orotracheal intubation rate at 14 days. Started Apr 2020; status: completed.
02
Drugs
nitazoxanide
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04561219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561219.